Most cited papers from Sana Klinikum Offenbach

Sana Klinikum Offenbach

What are the most cited papers from Sana Klinikum Offenbach?

The most cited paper from Sana Klinikum Offenbach is "Phases of Aβ-deposition in the human brain and its relevance for the development of AD" (Dietmar Rudolf Thal, Udo Rüb, Mario Orantes et al., 2002), with 3,605 citations. Next come "Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer" (2,689) and "Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy" (2,205).

Published TypeFieldAccessCitations

Showing 50 of 61 papers. Every paper with more than 160 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Phases of Aβ-deposition in the human brain and its relevance for the development of AD Dietmar Rudolf Thal, Udo Rüb, Mario Orantes et al. · Neurology	25 Jun 2002	3,605
2	Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer Gϋnter von Minckwitz et al. · New England Journal of Medicine Open access	5 Dec 2018	2,689
3	Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy Carsten Denkert et al. · The Lancet Oncology	8 Dec 2017	2,205
4	11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial David Cameron, Martine J Piccart, Richard D. Gelber et al. · The Lancet Open access	16 Feb 2017	1,052
5	Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial Gϋnter von Minckwitz et al. · The Lancet Oncology	30 Apr 2014	1,048
6	EULAR recommendations for the management of primary small and medium vessel vasculitis Chetan B. Mukhtyar, Loı̈c Guillevin, Maria Cinta Cid et al. · Annals of the Rheumatic Diseases Open access	15 Apr 2008	994
7	Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic Antibody—Associated Vasculitis Kirsten de Groot, Lorraine Harper, David R.W. Jayne et al. · Annals of Internal Medicine	19 May 2009	956
8	Long-term patient survival in ANCA-associated vasculitis Oliver Floßmann, Annelies E. Berden, Kirsten de Groot et al. · Annals of the Rheumatic Diseases	26 Nov 2010	946
9	Small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline Marco Pennazio et al. · Endoscopy Open access	31 Mar 2015	908
10	A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study S. Loibl et al. · Annals of Oncology Open access	7 May 2019	714
11	Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin Cyrile Anne Curat, Valérie Wegner, Coralie Sengenès et al. · Diabetologia Open access	22 Feb 2006	693
12	EULAR recommendations for the management of large vessel vasculitis Chetan B. Mukhtyar, Loı̈c Guillevin, Maria Cinta Cid et al. · Annals of the Rheumatic Diseases Open access	15 Apr 2008	675
13	Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial Luca Gianni et al. · The Lancet Oncology	26 Feb 2011	614
14	From Blood Monocytes to Adipose Tissue-Resident Macrophages Cyrile Anne Curat, Alexandra Miranville, Coralie Sengenès et al. · Diabetes Open access	May 2004	589
15	Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials Carsten Denkert et al. · The Lancet Oncology	9 Jul 2021	581
16	Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12 Emmanouil Fokas et al. · Journal of Clinical Oncology Open access	31 May 2019	556
17	2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Aron Goldhirsch et al. · The Lancet	17 Jul 2013	504
18	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response Evandro de Azambuja et al. · The Lancet Oncology	14 Aug 2014	461
19	Acute Cholecystitis Carsten N. Gutt et al. · Annals of Surgery	9 Aug 2013	460
20	Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial Michael Untch, Sibylle Loibl, Joachim Bischoff et al. · The Lancet Oncology	16 Jan 2012	459
21	Small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders: European Society of Gastrointestinal Endoscopy (ESGE) Technical Review Emanuele Rondonotti, Cristiano Spada, Samuel Nathan Adler et al. · Endoscopy Open access	14 Mar 2018	458
22	Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis Mark Alan Little, Peter Nightingale, Cornelis A. Verburgh et al. · Annals of the Rheumatic Diseases	3 Jul 2009	444
23	Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial David Cameron et al. · The Lancet Oncology	6 Aug 2013	443
24	Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial D. Jocham, Axel Richter, Lothar Hoffmann et al. · The Lancet	Feb 2004	436
25	Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up Lorraine Harper, Matthew David Morgan, Michael W. Walsh et al. · Annals of the Rheumatic Diseases Open access	Dec 2011	432
26	Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial Michael Untch et al. · The Lancet Oncology	8 Feb 2016	422
27	An Overview of PARP Inhibitors for the Treatment of Breast Cancer Laura Cortesi, Hope S. Rugo, Christian Jackisch · Targeted Oncology Open access	12 Mar 2021	400
28	Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer Eric Hahnen et al. · JAMA Oncology Open access	17 Jul 2017	398
29	ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286) Jens Hoeppner, Florian Lordick, Thomas Baptist Brunner et al. · BMC Cancer Open access	19 Jul 2016	360
30	Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial Gustavo Ismael, Roberto Hegg, Susanne Muehlbauer et al. · The Lancet Oncology	8 Aug 2012	352
31	A conformal index (COIN) to evaluate implant quality and dose specification in brachytherapy Dimos Baltas, Christos Kolotas, Konstantina Geramani et al. · International Journal of Radiation OncologyBiologyPhysics Open access	1998	330
32	Review of clinical brachytherapy uncertainties: Analysis guidelines of GEC-ESTRO and the AAPM Christian Kirisits, Mark J. Rivard, Dimos Baltas et al. · Radiotherapy and Oncology Open access	30 Nov 2013	315
33	Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto Sibylle Loibl et al. · Annals of Oncology Open access	15 Oct 2018	308
34	Indications for Surgery for Obesity and Weight-Related Diseases: Position Statements from the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Maurizio De Luca et al. · Obesity Surgery Open access	13 Jul 2016	297
35	German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors Henning Dralle et al. · Langenbeck s Archives of Surgery	Mar 2013	290
36	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group Carsten Denkert et al. · Modern Pathology Open access	Jul 2016	289
37	Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response Sibylle Loibl, Andreas Schneeweiß, Jens Huober et al. · Annals of Oncology Open access	9 Aug 2022	259
38	Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial Csaba Polgár et al. · The Lancet Oncology	13 Jan 2017	259
39	Functional Outcome Following Stroke Thrombectomy in Clinical Practice Frank Arne Wollenweber et al. · Stroke Open access	24 Jul 2019	255
40	Intensified Neoadjuvant Chemotherapy in Early-Responding Breast Cancer: Phase III Randomized GeparTrio Study Gϋnter von Minckwitz, Sherko Kümmel, P. Vogel et al. · JNCI Journal of the National Cancer Institute	8 Apr 2008	254
41	Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial Carsten Denkert, Sibylle Loibl, Berit Maria Müller et al. · Annals of Oncology Open access	23 Aug 2013	249
42	Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo Thomas Karn et al. · Annals of Oncology Open access	24 May 2020	241
43	Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01) Evandro de Azambuja, Marion Jennifer Procter, Dirk J. van Veldhuisen et al. · Journal of Clinical Oncology	10 Jun 2014	236
44	The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGI Salah‐Eddin Al‐Batran et al. · BMC Cancer Open access	Dec 2017	235
45	Improved Detection of Silent Atrial Fibrillation Using 72-Hour Holter ECG in Patients With Ischemic Stroke Martin Grond, Marek Jauss, Gerhard F. Hamann et al. · Stroke	16 Oct 2013	231
46	Second international consensus guidelines for breast cancer in young women (BCY2) Shani Paluch–Shimon, Olivia Pagani, Ann H. Partridge et al. · The Breast Open access	7 Feb 2016	230
47	Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies Matteo Lambertini, Marcello Ceppi, Francesca Benedetta Poggio et al. · Annals of Oncology ReviewOpen access	8 Sep 2015	229
48	Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis Alexandre Karras, Christian Pagnoux, Marion Haubitz et al. · Annals of the Rheumatic Diseases Open access	25 May 2017	212
49	Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial Michael Untch et al. · Annals of Oncology Open access	23 Feb 2008	198
50	Influence of the Angiotensin II Antagonist Valsartan on Left Ventricular Hypertrophy in Patients With Essential Hypertension Petra Thürmann, Peter Kenedi, Andor Schmidt et al. · Circulation Open access	10 Nov 1998	198

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.